AstraZeneca’s Ultomiris (ravulizumab) Receive EC’s Approval for the Treatment of Generalised Myasthenia Gravis
Shots:
- The EC has approved Ultomiris as an add-on to standard therapy for gMG in adult patients who are AChR Ab+
- The EC’s decision was based on the P-III (CHAMPION-MG) trial evaluating Ultomiris in a ratio (1:1) in 175 adult patients with gMG across North America, EU, Asia-Pacific & Japan for 26wks. The results showed that the therapy was superior to PBO in the 1EPs of change from baseline in MG-ADL total score @26wk. clinical benefits were seen @60wks. in prolonged follow-up results from OLE
- Reduction in treatment burden with dosing q8w & the results were published in NEJM Evidence, improvement in daily activities in patients with milder symptoms. The safety profiles were consistent with P-III trials in PNH & aHUS
Ref: AstraZeneca | Image: AstraZeneca
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
